Bristol Myers Execs Concede Cobenfi Needs Faster Starts, Explain Admilpirant's 120 mg Miss
Executives said Cobenfi must speed new patient starts, and one of 190 Zolacell patients died, as the company defended its paused CAR-T program.
Bristol Myers Squibb, the drugmaker behind Opdivo, Eliquis and the CAR-T therapy Breyanzi, faced pointed analyst questions on its third-quarter earnings call Thursday. The topics were a high dose of its pulmonary fibrosis drug that missed statistical significance, a slower-than-hoped Cobenfi launch, and a paused CAR-T program after a patient death.
The 120 mg dose question
A UBS analyst asked how confident the company remained in the 120 mg dose of admilpirant after mixed results in the idiopathic pulmonary fibrosis study. Chief Medical Officer Cristian Massacesi said the trial met its main goal at 60 mg, with statistically significant improvement in lung function, and that safety was strong at both 60 mg and 100 mg twice daily.
At 120 mg, he said, the company saw a change in lung function that was "not statistically significant." He noted the dose was never formally tested clinically in phase two; it was modeled, with a run-in period in phase three.
The coming progressive pulmonary fibrosis trial tests both doses. "We cannot predict what will be the outcome according to the doses," Massacesi said. Results are expected in the first quarter of next year, and full IPF data will go to a medical meeting next year.
Chief Commercialization Officer Adam Lenkowsky put today's IPF market at $4 billion and said it could nearly double as second-line switch and add-on use develops.
Cobenfi's uneven launch
A Wells Fargo analyst said Cobenfi's 30% year-over-year growth still looked modest against expectations for the schizophrenia drug. Lenkowsky agreed the brand had gaps: "we need to accelerate new patient starts" and to "improve repeat prescribing," he said.
He said too many patients stay on 50 or 100 milligram doses rather than the effective 125 milligrams, and that the number of prescribers has doubled from last year. Total prescriptions rose roughly 3% to 4% quarter on quarter, he said, while net sales were hit by an inventory drawdown after a second-quarter build that he expects to normalize in the fourth quarter.
CFO David Elkins reported Cobenfi revenue of $57 million, up 33%. Alzheimer's psychosis data from two open-label studies will be shown at CTAD in November.
Zolacell paused, defended
An RBC Capital Markets analyst asked about a phase one autoimmune CAR-T patient who died of sepsis pneumonia after a Zolacell infusion. Massacesi said it was the only grade 5 event, meaning a death, among 190 patients treated.
The program remains paused after a voluntary review of clinical data. Massacesi said the root cause was a change in how a reagent was selected and activated, that the company has adjusted it, and that it is working with regulators to restart the trial.
Chief Executive Chris Boerner said he sees "potentially transformational activity" and that the company will stay rigorous and transparent.
The quarter behind the questions
Elkins said revenue rose 7% to about $13.1 billion, with growth portfolio sales up 12% to $7.7 billion. Diluted earnings per share were $1.35, including a 58-cent hit from acquired in-process research and licensing items. The company raised full-year guidance, and non-GAAP EPS is now expected at $6.35 to $6.55.
Eliquis is expected to see a $1.5 billion to $2 billion step down in 2027, Elkins said.
Phase three progressive pulmonary fibrosis results for admilpirant are due in the first quarter of next year, and Cobenfi's Alzheimer's psychosis data arrive at CTAD in November.
Sources
- Bristol Myers: Q3 Earnings Snapshot — Associated Press
- Bristol Myers lifts sales outlook as newer drugs drive growth (BMY:NYSE) — seekingalpha.com
- Bristol-Myers Squibb Company Non-GAAP EPS of $1.35 beats by $0.13, revenue of $13.1B beats — seekingalpha.com
- Bristol Myers Squibb in charts: Legacy revenue rises 1%, while growth portfolio sales jump 12% | Seeking Alpha — seekingalpha.com
- Bristol-Myers Squibb Q3 2026 Earnings Preview (BMY:NYSE) | Seeking Alpha — seekingalpha.com